Disorders of the Human Neuromuscular Junction

Advances in Organ Biology

Volumn 2, Issue C, 1997, Pages 315-349

  Vincent, Angela ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0010424625     PISSN: 15692590     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1569-2590(08)60191-3     Document Type: Article

References (136)

1. Bain P.G., Motomura M., Newsom-Davis J., Misbah S.A., Chapel H.M., Lee M.L., Vincent A., and Lang B. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton syndrome. Neurology 47 (1996) 678-683
2. Barrett-Jolley R., Byrne N., Vincent A., and Newsom-Davis J. Seronegative myasthenia gravis plasmas reduce acetylcholine-induced currents in TE671 cells. Pflügers Archiv 428 (1994) 492-498
3. Beeson, D., Jacobson, L., Newsom-Davis, J., & Vincent, A. (1996). TE671 cells expressing adult human acetylcholine receptor for antibody assays in myasthnia gravis. Neurology 47 in press.
4. Beeson D., Morris A., Vincent A., and Newsom-Davis J. The human muscle nicotinic acetylcholine receptor alpha-subunit exists as two isoforms: a novel exon. EMBO J. 9 (1990) 2101-2106
5. Browne D.L., Gancher S.T., Nutt J.G., Brunt E.R.P., Smith E.A., Kramer P., and Lift M. Episodic ataxia/myokymia syndrome is associated with point mutations in the human potassium channel gene KCNA1. Nature Genet. 8 (1994) 136-140
6. Buchwald B., Weishaup A., Toyka K.V., and Dudel J. Immunoglobulin G from a patient with Miller-Fisher syndrome rapidly and reversibly depresses evoked quantal release at the neuromuscular junction. Neurosci Lett 201 (1995) 163-166
7. Burges J., Wray D.W., Pizzighella S., Hall Z., and Vincent A. A myasthenia gravis plasma immunoglobulin reduces miniature endplate potentials at human endplates in vitro. Muscle Nerve 13 (1990) 407-413
8. Camp S., Bon S., Li Y., Getman D.K., Engel A.G., Massoulié J., and Taylor P. Patients with congenital myasthenia associated with endplate acetylcholinesterase deficiency show normal sequence, mRNA splicing, and assembly of catalytic subunits. J. Clin. Invest. 94 (1995) 333-340
9. Cannon S.C. Ion-channel defects and aberrant excitability in myotonia and periodic paralysis. Trends Neurosci 19 (1996) 3-10
10. Cull-Candy S.G., Miledi R., Trautmann A., and Uchitel O.D. On the release of transmitter at normal, myasthenia gravis and myasthenic syndrome affected human end-plates. J Physiol. 299 (1980) 621-638
11. Drachman D.B., Angus D.W., Adams R.N., Michelson J.D., and Hoffman G.J. Myasthenia antibodies cross-link acetylcholine receptors to accelerate degradation. N. Engl. J. Med. 198 (1978) 1116-1122
12. Drachman D.B. Myasthenia gravis. N. Engl. J. Med. 330 (1994) 1797-1810
13. Drachman D.B., Mcintosh K.R., Reim J., and Balcer L. Strategies for treatment of myasthenia gravis. Ann. NY Acad. Sci. 681 (1993) 515-527
14. Eaton L.M., and Lambert E.H. Electromyography and electric stimulation of nerves in diseases of motor unit. Observations on myasthenic syndrome associated with malignant tumors. JAMA 163 (1957) 1117-1124
15. Elmqvist D., Hofmann W.W., Kugelberg J., and Quastel D.M.J. An electrophysiological investigation of neuromuscular transmission in myasthenia gravis. J Physiol. 174 (1964) 417-434
16. Elmqvist D., and Lambert E.H. Detailed analysis of neuromuscular transmission in a patient with the myasthenic syndrome sometimes associated with bronchogenic carcinoma. Mayo Clin. Proc. 43 (1968) 689-713
17. Engel A.G. Myasthenia gravis and myasthenic syndromes. Ann. Neurol. 16 (1984) 519-534
18. Engel A.G. The investigation of congenital myasthenic syndromes. Ann. NY Acad. Sci. 681 (1993) 425-434
19. Engel A.G. Review of evidence for loss of motor nerve terminal calcium channels in Lambert-Eaton myasthenic syndrome. Ann. NY Acad. Sci. 635 (1991) 246-258
20. Engel A.G., and Arahata K. The membrane attack complex of complement at the endplate in myasthenia gravis. Ann. NY Acad. Sci. 505 (1987) 326-332
21. Engel A.G., Lambert E.H., and Gomez M.R. A new myasthenic syndrome with end-plate acetylcholinesterase deficiency, small nerve terminals, and reduced acetylcholine release. Ann. Neurol. 1 (1977) 315-330
22. Engel A.G., Lambert E.H., Mulder D.M., Torres C.F., Sahashi K., Bertorini T.E., and Whitaker J.N. A Newly Recognized Congenital Myasthenic Syndrome Attributed to a Prolonged Open Time of the Acetylcholine-Induced Ion Channel. Ann. Neurol. 11 (1982) 553-569
23. Engel A.G., Lambert E.H., and Howard F.M. Immune complexes (IgG and C3) at the motor endplate in myasthenia gravis. Ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo. Clin. Proc. 52 (1977) 267-280
24. Engel A.G., Walls T.J., Nagel A., and Uchitel O. Newly recognized congenital myasthenic syndromes: I. Congenital paucity of synaptic vesicles and reduced quantal release. II. High-conductance fast-channel syndrome. III. Abnormal acetylcholine receptor (AChR) interaction with acetylcholine. IV. AChR deficiency and short channel-open time. Prog. Brain. Res. 84 (1990) 125-137
25. Fambrough D.M., Drachman D.B., and Satyamurti S. Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors. Science 182 (1973) 293-295
26. Fukunaga H., Engel A.G., Osame M., and Lambert E.H. Paucity and disorganisation of presynaptic membrane active zones in the Lambert-Eaton myasthenic syndrome. Muscle Nerve 5 (1982) 686-697
27. Fukunaga H., Engel A.G., Lang B., Newsom-Davis J., and Vincent A. Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. Proc. Natl. Acad. Sci. USA 80 (1983) 7636-7640
28. Fukuoka T., Engel A.G., Lang B., Newsom-Davis J., and Vincent A. Lambert-Eaton myasthenic syndrome: II. Immunoelectron microscopy localization of IgG at the mouse motor end-plate. Ann. Neurol. 22 (1987) 200-211
29. Garchon H.J., Djabiri F., Viard J.-P., Gajdos P., and Bach J.-F. Involvement of human muscle acetylcholine receptor alpha-subunit gene (CHRNA) in susceptibility to myasthenia gravis. Proc. Nat. Acad. USA 91 (1994) 4668-4672
30. Gautam M., Noakes P.G., Mudd J., Nichol M., Chu G.C., Sanes J.R., and Merlie J.P. Failure of postsynaptic specialization to develop at neuromuscular junctions of rapsyn-deficient mice. Nature 377 (1995) 232-236
31. Gautel M., Lakey A., Barlow D.P., Holmes Z., Scales S., Leonard K., Labeit S., Mygland A., Gilhus N.E., and Aarli J.A. Titin antibodies in myasthenia gravis: identification of a major immunogenic region of titin. Neurology 43 8 (1993) 1581-1585
32. Gomez C.M., Bhattacharyya B.B., Charnet P., Day J.W., Labarca C., Wollmann R.L., and Lambert E.H. A transgenic mouse model of the slow-channel syndrome. Muscle & Nerve 19 (1996) 79-87
33. Gomez C.M., and Richman D.P. Monoclonal anti-acetylcholine receptor antibodies with differing capacities to induce experimental autoimmune myasthenia gravis. J Immunol 135 (1985) 234-235
34. Gregson N.A., Jones D., Thomas P.K., and Willison H.J. Acute motor neuropathy with antibodies to GM1 ganglioside. Neurology 238 (1991) 447-451
35. Guyon T., Lavasseru P., Truffault F., Cottin C., Gaud C., and Berrih Aknin S. Regulation of acetylcholine receptor alpha subunit variants in human myasthenia gravis: Quantification of steady-state levels of messenger RNA in muscle biopsy using the polymerase chain reaction. J. Clin. Invest. 94 (1994) 16-24
36. Halbach M., Homberg V., and Freund H.-J. Neuromuscular, autonomic and central cholinergic hyperactivity associated with thymoma and acetylcholine receptor-binding antibody. J Neurol. (Berlin) 234 (1987) 433-436
37. Hall Z.W., and Sanes J.R. Synaptic structure and development: the neuromuscular junction. Cell 72 (1993) 99-121
38. Harcourt G.C., Sommer N., Rothbard J., Willcox H.N., and Newsom-Davis J. A juxta-membrane epitope on the human acetylcholine receptor recognized by T cells in myasthenia gravis. J. Clin. Invest. 82 (1988) 1295-1300
39. Hart S.H., Sahashi K., Lambert E.H., Engel A.G., and Lindstrom J.M. A congenital familial myasthenic syndrome caused by a presynaptic defect of transmitter resynthesis or mobilisation. Neurology 29 (1979) 557
40. Hart, I., Vincent, A., & Willison, H.J. (1996). Disorders of the motor nerve and motor nerve terminal. In: Myasthenia Gravis and Myasthenic Syndromes. (Engel, AG., ed.) Contemporary Topics in Neurology, CA Davis, in press.
41. Hart, I.K., Waters, C., Vincent, A., Newland, C., Beeson, D. Pongs, O., Morris, C., & Newsom-Davis, J. Autoantibodies detected to human brain potassium channels expressed in Xenopous oocytes are implicated in neuromyotonia (Isaacs' syndrome). Ann. Neurol, in press.
42. Natural and synthetic neurotoxins. In: Harvey A.L. (Ed). Neuroscience Perspectives (1993), Academic Press, San Diego
43. Harvey A.L., and Anderson A.J. Dendrotoxins: snake toxins that block potassium channels and facilitate neurotransmitter release. In: Harvey A. (Ed). Snake toxins (1991), Pergamon Press, Inc., New York 131-164
44. Harvey G.K., Toyka K.V., Jurgen Z., Kiefer R., Simonis C., and Hartung H.-P. Failure of anti-GM1 IgG or IgM to induce conduction block following intraneural transfer. Muscle Nerve 18 (1995) 388-394
45. Hawke S., Matsuo H., Nicolle M., Malcharek G., Melms A., and Willcox N. Autoimmune T cells in myasthenia gravis; heterogeneity and potential for specific immunotargeting. Immunology Today 17 (1996) 307-311
46. Hesselmans L., Jennekens F., van den Oord C., Veldman H., and Vincent A. Immunoreactivity to the acetylcholine receptor in developing human muscle. Anat. Rec. 236 (1993) 553-562
47. Ho T.W., Mishu B., Li C.Y., Gao C.Y., Cornblath D.R., Griffin J.W., Asbury A.K., Blaser M.J., and McKhann G.M. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 118 (1995) 597-605
48. Hutchinson D.O., Walls T.J., Nakano S., Camp S., Taylor P., Harper C.M., Groover R.V., Peterson H.A., Jamieson D.G., and Engel A.G. Congenita] endplate acetylcholinesterase deficiency. Brain 116 (1993) 633-653
49. Isaacs H. A syndrome of continuous muscle-fiber activity. J Neurol Neurosurg Psychiatry 24 (1961) 319-325
50. Ito Y., Miledi R., Vincent A., and Newsom-Davis J. Acetylcholine receptors and end-plate electrophysiology in myasthenia gravis. Brain 101 (1978) 345-368
51. Jennekens F.G.I., Hesselmans L.F.G.M., Veldman H., Jansen E.N.H., Spaans F., and Molenaar P.C. Deficiency of acetylcholine receptors in a case of end-plate acetylcholinesterase deficiency: A histochemical investigation. Muscle Nerve 15 (1992) 63-72
52. Johnston I., Lang B., Leys K., and Newsom-Davis J. Heterogeneity of calcium channel autoantibodies detected using a small cell lung cancer line derived from a Lambert-Eaton syndrome patient. Neurology 44 (1994) 334-338
53. Kaminski H.J., Maas E., Spiegel P., and Ruff R.L. Why are eye muscles frequently involved in myasthenia gravis. Neurology 40 (1990) 1663-1669
54. Kaminski H.J., Fenstermaker R.A., Abdul Karim F.W., Clayman J., and Ruff R.L. Acetylcholine receptor subunit gene expression in thymic tissue. Muscle Nerve 16 12 (1993) 1332-1337
55. Karlin A., and Akabas M.H. Toward a structural basis for the function of nicotinic acetylcholine receptors and their cousins. Neuron 15 (1995) 1231-1244
56. Kim Y.I., Sanders D.B., Johns T.R., Phillips L.H., and Smith R.E. Lambert-Eaton myasthenic syndrome: the lack of short-term in vitro effects of serum factors on neuromuscular transmission. J. Neurol. Sci. 87 (1988) 1-13
57. Kim Y.I., and Neher E. IgG from patients with Lambert-Eaton syndrome blocks voltage dependent calcium channels. Science 239 (1988) 405-408
58. Lafontaine S., Rasminsky M., Saida T., and Sumner A.J. Conduction block in rat myelinated fibres following acute exposure to anti-galactocerebroside serum. J. Physiol. 323 (1982) 287-306
59. Lambert E.H., and Elmqvist D. Quantal components of end-plate potentials in the myasthenic syndrome. Ann. NY Acad. Sci. 183 (1971) 183-199
60. Lang B., Newsom-Davis J., Wray D., Vincent A., and Murray N.M.F. Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet ii (1981) 224-226
61. Lang B., Newsom-Davis J., Prior C., and Wray D. Antibodies to motor nerve terminals: an electrophysiological study of a human myasthenic syndrome transferred to mouse. J. Physiol. 344 (1983) 335-345
62. Latov N. Antibodies to glycoconjugates in neurological disease. Clin. Aspects Autoimmunity 4 (1990) 18-29
63. Lennon V.A., Kryzer T.J., Griesmann G.E., O'Suilleabhain P.E., Windebank A.J., Woppmann A., Miljanich G.P., and Lambert E.H. Calcium channel antibodies in the Lambert Eaton myasthenic syndrome and other paraneoplastic syndromes. New Eng. J. Med. 332 (1995) 1467-1474
64. Lennon V.A., and Lambert E.H. Myasthenia gravis induced by monoclonal antibodies to acetylcholine receptors. Nature 285 (1980) 238-240
65. Lennon V.A., Lambert E.H., Whittingham S., and Fairbanks V. Autoimmunity in the Lambert-Eaton myasthenic syndrome. Muscle Nerve 5 (1982) S21-S25
66. Leveque C., Hoshino T., David P., Shoji-Kasai Y., Leys K., Omori A., Lang B., El Far O., Sato K., Martin-Moutot N., Newsom-Davis J., Takahashi M., and Seagar M.J. The synaptic vesicle protein synaptotagmin associates with calcium channels and is a putative Lambert-Eaton myasthenic syndrome antigen. Proc. Natl. Acad. Sci. USA 89 (1992) 3625-3629
67. Li, Z., Forester, N., & Vincent, A. Modulation of acetylcholine receptor function in TE671 (rhabdomyosarcoma) cells by non-AChR ligands; a role in seronegative myasthenia gravis? J. Neuroimmunol 64, 179-184.
68. Lindstrom J.M., Seybold M.E., Lennon V.A., Whittingham S., and Duane D.D. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates and diagnostic value. Neurology 26 (1976) 1054-1059
69. Login I.S., Kim Y.I., Judd A.M., Spangelo B.L., and MacLeod R.M. Immunoglobulins of Lambert-Eaton myasthenic syndrome inhibit rat pituitary hormone release. Ann. Neurol. 22 (1987) 610-614
70. MacLennan C., Beeson D., Vincent A., and Newsom-Davis J. Human nicotinic acetylcholine receptor α-subunit isoforms: origins and expression. Nucleic Acids Res. 21 (1993) 5463-5467
71. Marx A., Kirchner T., Greiner A., Muller Hermelink H.K., Schalke B., and Osborn M. Neurofilament epitopes in thymoma and antiaxonal autoantibodies in myasthenia gravis. Lancet 339 (1992) 707-708
72. Milone M., Hutchinson D.O., and Engel A.G. Patch-Clamp Analysis of the Properties of Acetylcholine Receptor Channels at the Normal Human Endplate. Muscle Nerve 17 (1994) 1364-1369
73. Molenaar P.C., Newsom-Davis J., Polak R.L., and Vincent A. Eaton-Lambert syndrome: acetylcholine and choline acetyltransferase in skeletal muscle. Neurology 32 (1982) 1062-1065
74. Mora M., Lambert E.H., and Engel A.G. Synaptic vesicle abnormality in familial infantile myasthenia. Neurology 37 (1987) 206-214
75. Motomura M., Johnston I., Lang B., Vincent A., and Newsom-Davis J. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J. Neurol. Neurosurg. Psychiatry 58 (1995) 85-87
76. Murray N.M.F., and Newsom-Davis J. Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission. J. Physiol 421 (1990) 293-308
77. Mygland A., Tysnes O.-B., Matre R., Volpe P., Aarli J.A., and Gilhus N.-E. Ryanodine receptor autoantibodies in myasthenia gravis patients with a thymoma. Ann. Neurol. 32 (1992) 589-591
78. Nagel A., Engel A.G., Lang B., Newsom-Davis J., and Fukuoka T. Lambert-Eaton myasthenic syndrome IgG depletes presynaptic membrane active zone particles by antigenic modulation. Ann. Neurol. 24 (1988) 552-558
79. Newland C.F., Beeson D., Vincent A., and Newsom-Davis J. Functional and non-functional isoforms of the human muscle acetylcholine receptor. J. Physiol. (Lond) 489 (1995) 767-778
80. Newland C.F., Croxen R., Beeson D., Vincent A., and Newsom-Davis J. Mutations in human muscle ACh receptor in congenital myasthenia prolong receptor activations. J. Physiol (Lond) 495 (1996) 79P
81. Newsom-Davis J., Pinching A.J., Vincent A., and Wilson S.G. Function of circulating antibody to acetylcholine receptor in myasthenia gravis: investigation by plasma exchange. Neurology 28 (1978) 266-272
82. Newsom-Davis J., and Murray N.M. Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology 34 (1984) 480-485
83. Newsom-Davis, J., & Lang, B. The Lambert Eaton Myasthenic Syndrome. In: Myasthenia Gravis and Myasthenic Syndromes (Engel, A.E., ed.) Contemporary Topics in Neurology. CA Davis. In press.
84. Newsom-Davis J., and Mills K.R. Immunological associations of acquired neuromyotonia (Isaacs' syndrome). Report of five cases and literature review. Brain 116 (1993) 453-469
85. + lymphocytes by soluble major histocompatibility complex class II-peptide complexes. J. Clin. Invest. 93 (1994) 1361-1369
86. Noakes P.G., Gautam M., Mudd J., Sanes J.R., and Merlie J. Aberrant differentiation of neuromuscular junctions in mice lacking s-laminin/laminin ß2. Nature 374 (1995) 258-266
87. Oda K., and Shibasaki H. Antigenic difference of acetylcholine receptor between single and multiple form endplates of human extraocular muscle. Brain Res. 449 (1988) 337-340
88. Ohno K., Hutchinson D.O., Milone M., Brengman J.M., Bouzat C., Sine S.M., and Engel A.G. Congenital Myasthenic syndrome caused by prolonged acetylcholine receptor channel openings due to a mutation in the M2 domain of the ε{lunate} subunit. Proc. Natl. Acad. Sci. USA 92 (1995) 758-762
89. Olivera B.M., Miljanich G.P., Ramachandran J., and Adams M.E. Calcium channel diversity and neurotransmitter release: the ω-conotoxins and ω-Agatoxins. Ann. Rev. Biochem. 63 (1994) 823-867
90. O'Neill J.H., Murray N.M., and Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 111 (1988) 577-596
91. Oosterhuis H.J., Newsom-Davis J., Wokke J.H., Molenaar P.C., Weerden T.V., Oen B.S., Jennekens F.G., Veldman H., Vincent A., Wray D.W., et al. The slow channel syndrome. Two new cases. Brain 110 (1987) 1061-1079
92. Patrick J., and Lindstrom J. Autoimmune response to acetylcholine receptor. Science 180 (1973) 871-872
93. Peers C., Johnston I., Lang B., and Wray D. Cross-linking of presynaptic calcium channels: a mechanism of action for Lambert-Eaton myasthenic syndrome antibodies at the mouse neuromuscular junction. Neurosci Let. 153 (1993) 45-48
94. Peers C., Lang B., Newsom-Davis J., and Wray D.W. Selective action of myasthenic syndrome antibodies on calcium channels in a rodent neuroblastoma x glioma cell line. J. Physiol. 421 (1990) 293-308
95. Plomp J.J., Van-Kempen G.T.H., De Baets M., Graus Y.M.F., Kuks J.B.M., and Molenaar P.C. Acetylcholine release in myasthenia gravis: Regulation at single end-plate level. Ann. Neurology 37 (1995) 627-636
96. Rees J.H., Soudain S.E., Gregson N.A., and Hughes R.A.C. Campylobacter jejuni infection and guillain-Barré syndrome. New Eng. J. Med. 333 (1995) 1374-1379
97. Roberts M., Willison H.J., Vincent A., and Newsom-Davis J. Serum factor in the Miller Fisher variant of Guillain-Barré syndrome and neurotransmitter release. Lancet 343 (1994) 454-455
98. Roberts M., Willison H.J., Vincent A., and Newsom-Davis J. Multifocal motor neuropathy human sera block distal motor nerve conduction in mice. Ann. Neurol. 38 (1995) 111-118
99. 2+ flux in a human small cell carcinoma line. Nature 317 (1985) 737-739
100. Santoro M., Thomas F.P., Fink M.E., et al. IgM deposits at nodes of Ranvier in a patient with motor neuropathy, anti-GM1 antibodies and multifocal motor conduction block. Ann. Neurol 28 (1990) 373-379
101. Scadding G.K., Vincent A., Newsom-Davis J., and Henry K. Acetylcholine receptor antibody synthesis by thymic lymphocytes: correlation with thymic histology. Neurology 31 (1981) 935-943
102. Schluep M., Willcox N., Vincent A., Dhoot G.K., and Newsom-Davis J. Acetylcholine receptors in human thymic myoid cells in situ: an immunohistological study. Ann. Neurol. 22 (1987) 212-222
103. Shillito P., Molenaar P.C., Vincent A., et al. Acquired neuromyotonia: evidence for autoantibodies against K+ channels of peripheral nerves. Ann Neurol. 38 (1995) 714-722
104. Shillito P., Vincent A., and Newsom-Davis J. Congenital myasthenic syndromes. Neuromusc Disord 3 (1993) 183-190
105. Simpson J.A. Myasthenia gravis: a new hypothesis. Scott Med J 5 (1960) 419-439
106. Sine S.M., Ohno K., Bouzat C., Auerbach A., Milone M., Pruitt J.N., and Engel A.G. Mutation of the acetylcholine receptor α subunit causes a slow-channel myasthenic syndrome by enhancing agonist binding affinity. Neuron 15 (1995) 229-239
107. Sinha S., Newsom-Davis J., Mills K., Byrne N., Lang B., and Vincent A. Autoimmune aetiology for acquired neuromyotonia (Isaacs' syndrome). Lancet 338 (1991) 75-77
108. Smith R.G., Hamilton S., Hofman P., Schneider T., Nastainczyk W., Birnbaumer L., Stefani E., and Appel Sh. Serum antibodies to L-type calcium channe;ls in patients with amyotrophic lateral sclerosis. New Eng. J. Med. 327 (1992) 1721-1728
109. Spack E.G., McCutcheon M., Corbellatta N., Nag B., Passmore D., and Sharma S.D. Induction of tolerance in experimental autoimmune myasthenia gravis with solubilized MHC class II: acetylcholine receptor peptide complexes. J. Autoimm. 8 (1995) 787-808
110. Stanley E.F., and Drachman D.B. Effect of myasthenic immunoglobulin on acetylcholine receptors of intact mammalian neuromuscular junctions. Science 200 (1978) 1285-1287
111. + currents in isolated rat myelinated nerve fibers. Ann. Neurol. 37 (1995) 436-442
112. Toyka K.V., Drachman D.B., Griffin D.E., Pestronk A., Winkelstein J.A., Fischbeck K.H., and Kao I. Myasthenia gravis: study of humoral immune mechanisms by passive transfer to mice. N. Engl. J. Med. 296 (1977) 125-131
113. Toyka K.V., Drachman D.B., Griffin D.E., Pestronk A., Winkelstein J.A., Fischbeck K.H., and Kao I. Myasthenia gravis: study of humoral immune mechanisms by passive transfer to mice. N.Engl. J. Med. 296 (1977) 125-131
114. Tzartos S.J., Barkas T., Cung M.T., et al. The main immunogenic region of the acetylcholine receptor: structure and role in myasthenia gravis. Autoimmunity 8 (1991) 259-270
115. Tzartos S.J., Seybold M.E., and Lindstrom J.M. Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies. Proc. Natl. Acad. Sci. USA 79 (1982) 188-192
116. Van der Kloot W., and Molgó J. Quantal acetylcholine release at the vertebrate neuromuscular junction. Physiol Rev. 74 (1994) 900-991
117. Vincent A. Immunology of acetylcholine receptors in relation to myasthenia gravia. Physiol Rev 60 (1980) 756-824
118. Vincent A. Aetiological factors in development of myasthenia gravis. Adv Neuroimmunology 4 (1994) 355-371
119. Vincent A., Beeson D., and Newsom-Davis J. α-neurotoxin binding to the human nicotinic acetylcholine receptr. Biochem Soc Trans 18 (1990) 42
120. Vincent A., Cull-Candy S., Newsom-Davis J., Trautmann A., Molenaar P.C., and Polak R. Congenital myasthenia: endplate acetylcholine receptors and electrophysiology in five cases. Muscle Nerve 4 (1981) 306-318
121. Vincent A., Li Z., Hart A., Barrett-Jolley R., Yamamoto T., Burges J., Wray D., Byrne N., Molenaar P., and Newsom-Davis J. Seronegative myasthenia gravis; evidence for plasma factor(s) interfering with acetylcholine receptor function. Ann. NY Acad. Sci. 681 (1993) 529-538
122. Vincent A., Newland C., Brueton L., Beeson D., Riemersma S., Huson S.M., and Newsom-Davis J. Arthrogryposis multiplex congenita with maternal autoantibodies specific for a fetal antigen. Lancet 346 (1995) 24-25
123. Vincent A., and Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J. Neurol. Neurosurg. Psychiatry 48 (1985) 1246-1252
124. Vincent A., Newsom-Davis J., Wray D., Shillito P., Harrison J., Betty M., Beeson D., Mills K., Palace J., Molenaar P., and Murray N. Clinical and experimental observations in patients with congenital myasthenic syndromes. Ann. NY Acad. Sci. 681 (1993) 451-460
125. Vincent A., Whiting P.J., Schluep M., et al. Antibody heterogeneity and specificity in myasthenia gravis. Ann NY Acad Sci 505 (1987) 326-332
126. In: Vincent A., and Wray D. (Eds). Neuromuscular Transmission; Basic and Applied Aspects (1992), Pergammon Press, Oxford
127. Walls T.J., Engel A.G., Nagel A.S., Harper C.M., and Trastek V.F. Congenital myasthenic syndrome associated with paucity of synaptic vesicles and reduced quantal release. Ann. New York Acad. Sci. 681 (1993) 461-467
128. Waxman S., and Ritchie M. Molecular dissection of the myelinated axon. Ann. Neurology 33 (1993) 121-136
129. Whiting P.J., Vincent A., and Newsom-Davis J. Myasthenia gravis: monoclonal antihuman acetylcholine receptor antibodies used to analyze antibody specificities and responses to treatment. Neurology 36 (1986) 612-617
130. Willcox N., Demaine A.G., Newsom-Davis J., Welsh K.I., Robb S.A., and Spiro S.G. Increased frequency of IgG heavy chain marker Glm(2) and of HLA-B8 in Lambert-Eaton myasthenic syndrome with and without associated lung carcinoma. Hum Immunol 14 (1985) 29-36
131. Willison H.J. Antiglycolipid antibodies in peripheral neuropathies: fact or fiction?. J. Neurol. Neurosurg. Psychiatry 57 (1994) 1303-1307
132. Willison, H.J., O'Hanlon, G.M., Paterson, G., Veitch, J., Wilson, G., Roberts, M., Tang, T., & Vincent, A. A somatically mutated human anti-ganglioside IgM antibody that induces experimental neuropathy in mice is encoded by the variable region heavy chain gene, V1-18. J. Clin. Invest., 97, 1155-1164.
133. Wilson S., Vincent A., and Newsom-Davis J. Acetylcholine receptor turnover in mice with passively transferred myasthenia gravis. II. Receptor synthesis. J. Neurol. Neurosurg. Psychiatry 46 (1983) 383-387
134. Wokke J.H., Jennekens F.G.I., Molenaar P.C., Van den Ord C.J.M., Oen B.S., and Busch H.F.M. Congenital paucity of secondary synaptic clefts (CPSC) syndrome in two adult sibs. Neurology 39 (1990) 648-654
135. Yamamoto T., Vincent A., Ciulla T.A., Lang B., Johnston I., and Newsom-Davis J. Seronegative myasthenia gravis: A plasma factor inhibiting agonist-induced acetylcholine receptor function copurifies with IgM. Ann. Neurol. 30 (1991) 550-557
136. Yuki N., Taki T., Inagaki F., et al. A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J. Exp. Med. 178 5 (1993) 1771-1775